Hansoh Pharmaceutical Group launched on Thursday Hong Kong’s second-largest initial public offering this year, looking for as much as HK$7.8 billion ($1 billion) as the Chinese generic drug manufacturer tries to draw investor attention away from a focus on biotech companies.
¬ Haymarket Media Limited. All rights reserved.
